A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

Subject: Schizophrenia - PUBLISHED VIA Current Pharmaceutical Design

Author(s):
Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimarães FS

Department of Neuroscience and Behavior, Faculty of Medicine, University of São Paulo and National Institute for Translational Medicine, Ribeirão Preto, SP-Brazil

 View Source >>

Related Studies:

Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

Published via Drug Testing and Analysis

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Published via Brazilian Journal of Medical and Biological Research

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Published via Translational Psychiatry

Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Published via Neuropsychopharmacology

Cannabidiol as a potential treatment for psychosis.

Published via European Neuropsychopharmacology

View all medical studies

Learn More About Cannabis

Website & branding by the Ganjapreneur in-house agency:

Blue Dream - Uplifted cannabis industry branding & marketing.

Uplifted cannabis industry branding & marketing.